Navigation Links
Taiho Pharmaceutical Invests US$30 Million in Remiges BioPharma Fund, LP
Date:7/22/2014

TOKYO, July 23, 2014 /PRNewswire/ -- 

- Investment to Foster Early Biotech Start-ups -

Taiho Pharmaceutical Co., Ltd. (hereinafter "Taiho"), a fully-fledged oncology pharmaceutical company, announced on July 23 that the company will be investing US$30 million in Remiges BioPharma Fund (hereinafter "Remiges Fund"), a newly formed biotech venture capital fund.

Taiho has a long history of developing new therapeutic options to serve the needs of oncologists and cancer patients. Our development of TAS-102 is an example of our commitment to patients diagnosed with metastatic colorectal cancer whose disease progressed after or who were intolerant to standard therapies. At the same time, we recognize the importance of collaborating with academia and biotech ventures outside Japan for efficient and effective biopharmaceutical innovation.

Taiho hopes to use the investment in Remiges Fund as the platform for open innovation - an outreach for innovative technologies. Through Remiges' well-connected US-Japan cross border investment team, Taiho will be tapping into the US/Europe biotech start-up community and catalyze the company's R&D to deliver innovative cancer treatment to patients.

About Taiho Pharmaceutical Co., Ltd.

Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd., is an R&D-driven specialty pharma focusing on the three fields of oncology, allergies and immunology, and urology. Its corporate philosophy takes the form of a pledge: "We strive to improve human health and contribute to a society enriched by smiles." In the field of oncology in particular, Taiho Pharmaceutical is known as a leading company in Japan and around the world for developing innovative medicines for the treatment of cancer. In areas other than oncology, as well, the company creates quality products that effectively treat medical conditions and can help improve people's quality of life. Always putting customers first, Taiho Pharmaceutical also aims to offer over-the-counter medicinal products that support people's efforts to lead fulfilling and rewarding lives.

Headquarters: Tokyo
President: Masayuki Kobayashi

For more information about Taiho Pharmaceutical, please visit
http://www.taiho.co.jp/english/


'/>"/>
SOURCE Taiho Pharmaceutical Co., Ltd.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
2. Taiho Pharmaceutical présente une demande dhomologation pour la fabrication et la commercialisation du nouvel agent antitumoral TAS-102
3. Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market Novel Antitumor Agent TAS-102
4. Taiho Pharmaceutical stellt Zulassungsantrag zur Herstellung und Vermarktung des neuartigen Antitumormittels TAS-102
5. Taiho Pharmaceutical presenta una solicitud para fabricar y comercializar el nuevo agente antitumoral TAS-102
6. Taiho Pharmaceutical ansöker om godkännande att tillverka och sälja det nya antitumörpreparatet TAS-102
7. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
8. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
9. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
10. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
11. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE ... Bloom Burton & Co. Healthcare Investor Conference 2017 at the Sheraton ... Edward Wright , Chief Executive Officer of the Company is scheduled ... CFO, Richard Bear and the Chairman of the Board, ... ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 The ... anticipated to showcase a healthy CAGR during the forecast period ... product type in the global digital mobile X-Ray devices market, ... 2,000 Mn in 2017, expanding at a CAGR of 7% ... create absolute $ opportunity of more than US$ 100 Mn ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 ... Surgical drainage devices are tubes used to remove excess ... include, blood, serum, pus, urine, bile or lymph. Surgical ... types of surgery such as orthopedics surgery, cardiovascular surgery, ... device is prophylactic post-surgery to prevent accumulation of fluid ...
Breaking Medicine Technology:
(Date:4/22/2017)... ... ... Juan Capistrano summer camp team at the Boys and Girls Club of South Coast ... physical activities for all campers. To read the report, click here or see ... specialty camps that focus on what the report terms as “sitting subjects” like coding or ...
(Date:4/21/2017)... ... April 21, 2017 , ... Chicago plastic surgeon, Dr. Anil ... An osteoma is a benign bony lump located on the forehead usually attributed to ... difficulties with sight and pain. Dr. Shah has discovered an approach that is minimally ...
(Date:4/21/2017)... ... ... The adage “Show, don’t tell” applies perfectly to Green Builder Media’s Earth ... House demonstration project series. Manifesting the concept of right-sized living, the Flex House is ... affordably and abundantly without unduly taxing the resources of our beautiful planet. ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... campaign, AWARE: A Week of Addiction and Recovery Education, from April 24 to ... and preventing substance use disorders. , The mission of AWARE is to ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... candidates to serve on its Accreditation and Standards Committees to support the ... is improving image quality and reducing patient radiation dose,” reports Eliot Siegel, ...
Breaking Medicine News(10 mins):